HOLON, Israel, Oct. 7, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced, that new
clinical data supporting the anti-tumor activity and safety of the
triple combination COM701, COM902 and pembrolizumb in heavily
pre-treated patients with platinum resistant ovarian cancer will be
presented at the 39th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), taking place between November 8-10, 2024, in Houston, Texas.
Poster presentation details:
Abstract Title: Triple blockade of DNAM-1axis with COM701
(anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows
preliminary antitumor activity in patients with platinum resistant
ovarian cancer, interim results of Phase I trial
Abstract number: 985
Presenter: Dr. Oladapo Yeku,
Medical Oncologist, Massachusetts General Hospital
Date: Friday, November 8,
2024
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery platform (UnigenTM) to identify
new drug targets and biological pathways for developing cancer
immunotherapies. Compugen has two proprietary product
candidates in Phase 1 development: COM701, a potential
first-in-class anti-PVRIG antibody and COM902, a potential
best-in-class antibody targeting TIGIT for the treatment of solid
tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the
TIGIT component is derived from Compugen's clinical stage
anti-TIGIT antibody, COM902, is in Phase 3 development by
AstraZeneca through a license agreement for the development of
bispecific and multispecific antibodies. In addition, the
Company's therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms
of immune resistance, of which the most advanced program, COM503, a
potential first-in-class, high affinity anti-IL-18 binding protein
antibody, which has been granted IND clearance from the FDA, is
licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-new-clinical-data-at-sitc-2024-302268683.html
SOURCE Compugen Ltd.